Skip to content
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
BioTechGrid BioTechGrid
  • Home
  • Biotechnology
  • Medical Technology
  • Research
  • Genetics
  • Press Releases
    • Business Wire
    • GlobeNewswire
    • PRNewswire
  • Contact
  • Home
  • Biotechnology
  • Apnimed aspires for up to $160M IPO as sleep apnea pill launch nears

Apnimed aspires for up to $160M IPO as sleep apnea pill launch nears

July 27, 2026Posted inBiotechnology

Apnimed has detailed its plans for an initial public offering, with the biotech intending to raise as much as $160 million to fund the launch of its sleep apnea pill.

Post navigation

Previous Post
MapLight shares sink on mixed phase 2 schizophrenia readout
Next Post
RA Capital launches rare disease company Oak Hill Bio onto Nasdaq via SPAC

Recent Posts

  • Modeling Reveals How Silica Gold Nanoparticles Reshape Optical Energy and Fields
  • Intravenous Iron Formulations Spur Divergent Muscle Recovery in Iron Deficiency Anaemia
  • SAR and optical data fuse in dynamic graph network to classify sea ice with 96.69% accuracy
  • Grid access cuts solar adoption odds in Cameroon, study finds
  • CT Histogram Radiomics Accurately Distinguishes Middle Ear Cholesteatoma

Archives

  • November 2026
  • October 2026
  • September 2026
  • August 2026
  • July 2026
  • September 2024
  • August 2024
  • March 2024
  • September 2023

Privacy Policy    Terms

Scroll to Top